The combination of SBRT (30 Gy in 3 fractions) and anti-PD-1 antibodies markedly suppressed tumor growth and improved survival with increased infiltration of CD8+ cytotoxic T cells within the tumor. The gene discussed is CD8A; the disease is neoplasm.